Linked Life Data

6427489

Source:http://linkedlifedata.com/resource/pubmed/id/6427489

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
1984-7-3
pubmed:abstractText
Using recently published information, we examined the experience of a hypothetical cohort of 1 million children followed up from birth to 6 years of age without and with a pertussis vaccination program. Costs associated with death or lost wages were not estimated. A vaccination program reaching 90% of children would reduce disease incidence and disease-related costs by 90%. Taking into account costs associated with vaccine and vaccine reactions, the costs are reduced 82%. The ratio of overall costs without a program to those with a program is 5.7:1. The benefit-cost ratio is 11.1:1. Because we did not include indirect costs, this is a conservative estimate. Until improved vaccines are available, continued use of our present vaccines, with careful attention to possible contraindications, seems the only prudent course to follow.
pubmed:keyword
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0098-7484
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
251
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3109-13
pubmed:dateRevised
2006-11-7
pubmed:otherAbstract
KIE: An analysis was performed on the experience of a hypothetical cohort of one million children followed from birth to 6 years of age with and without a pertussis vaccination program. The results indicated that a vaccination program reaching 90% of children would reduce disease incidence and disease-related costs by 90%. Based on a conservative approach that considered only direct costs associated with vaccine and vaccine reactions, the authors calculated that the benefit-cost ratio of an immunization program is 11.1:1. They conclude that, until improved vaccines are developed, it is prudent to continue use of present vaccines with careful attention to possible contraindications.
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs.
pubmed:publicationType
Journal Article